• 541 Citations
  • 14 h-Index
20062020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Raquibul Hannan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 541 Citations
  • 14 h-Index
  • 35 Article
  • 1 Letter
  • 1 Review article

Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]

Correa, R. J. M., Louie, A. V., Zaorsky, N. G., Lehrer, E. J., Ellis, R., Ponsky, L., Kaplan, I., Mahadevan, A., Chu, W., Swaminath, A., Hannan, R., Onishi, H., Teh, B. S., Muacevic, A., Lo, S. S., Staehler, M. & Siva, S., Jan 1 2020, (Accepted/In press) In : European Urology Focus.

Research output: Contribution to journalLetter

Open Access

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L., Xie, Z., Chen, M., Luke, J. J., Brugarolas, J., Hannan, R. & Wang, T., Feb 21 2020, In : Science Immunology. 5, 44

Research output: Contribution to journalArticle

  • Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity

    Zhang, F., Manna, S., Pop, L. M., Chen, Z. J., Fu, Y. X. & Hannan, R., Apr 2020, In : Seminars in Radiation Oncology. 30, 2, p. 129-138 10 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations
  • Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG Oncology RTOG 0521 Trial

    Rosenthal, S. A., Hu, C., Sartor, O., Gomella, L. G., Amin, M. B., Purdy, J., Michalski, J. M., Garzotto, M. G., Pervez, N., Balogh, A. G., Rodrigues, G. B., Souhami, L., Reaume, M. N., Williams, S. G., Hannan, R., Horwitz, E. M., Raben, A., Peters, C. A., Feng, F. Y., Shipley, W. U. & 1 others, Sandler, H. M., Jan 1 2019, In : Journal of Clinical Oncology. 37, 14, p. 1159-1168 10 p.

    Research output: Contribution to journalArticle

  • 24 Scopus citations